Global Disparities in Hepatitis B Elimination—A Focus on Africa
Abstract
:1. Introduction
2. Disparities in Eliminating Mother-to-Child and Early Childhood Transmission
3. Disparities in the Treatment of Chronic Hepatitis B Virus Infection
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- WHO. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections; World Health Organization: Geneva, Switzerland, 2021. [Google Scholar]
- WHO. Viral Hepatitis Scorecard. 2019. Available online: https://www.afro.who.int/publications/hepatitis-scorecard-who-africa-region-implementing-hepatitis-elimination-strategy (accessed on 21 December 2021).
- de Villiers, M.J.; Nayagam, S.; Hallett, T.B. The impact of the timely birth dose vaccine on the global elimination of hepatitis B. Nat. Commun. 2021, 12, 6223. [Google Scholar] [CrossRef] [PubMed]
- WHO. WHO Global Health Sector Strategy on Viral Hepatitis 2016–2021; WHO: Geneva, Switzerland, 2016. [Google Scholar]
- Collaborators, P.O.; Razavi, H.; Blach, S.; Razavi-Shearer, D.; Abaalkhail, F.; Abbas, Z. The case for simplifying and using absolute targets for viral hepatitis elimination goals. J. Viral Hepat. 2021, 28, 12–19. [Google Scholar] [CrossRef]
- Schmit, N.; Nayagam, S.; Thursz, M.R.; Hallett, T.B. The global burden of chronic hepatitis B virus infection: Comparison of country-level prevalence estimates from four research groups. Int. J. Epidemiol. 2020, 50, 560–569. [Google Scholar] [CrossRef] [PubMed]
- Razavi-Shearer, D.; Gamkrelidze, I.; Nguyen, M.H.; Chen, D.S.; Van Damme, P.; Abbas, Z.; Abdulla, M.; Abou Rached, A.; Adda, D.; Aho, I.; et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol. Hepatol. 2018, 3, 383–403. [Google Scholar] [CrossRef]
- Maynard, J.E. Hepatitis B: Global importance and need for control. Vaccine 1990, 8, S18–S20. [Google Scholar] [CrossRef]
- Dumpis, U.; Holmes, E.C.; Mendy, M.; Hill, A.; Thursz, M.; Hall, A.; Whittle, H.; Karayiannis, P. Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. J. Hepatol. 2001, 35, 99–104. [Google Scholar] [CrossRef]
- Matthews, P.C.; Geretti, A.M.; Goulder, P.J.; Klenerman, P. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J. Clin. Virol. 2014, 61, 20–33. [Google Scholar] [CrossRef] [PubMed]
- Ott, J.J.; Stevens, G.A.; Groeger, J.; Wiersma, S.T. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012, 30, 2212–2219. [Google Scholar] [CrossRef] [Green Version]
- Shimakawa, Y.; Yan, H.J.; Tsuchiya, N.; Bottomley, C.; Hall, A.J. Association of early age at establishment of chronic hepatitis B infection with persistent viral replication, liver cirrhosis and hepatocellular carcinoma: A systematic review. PLoS ONE 2013, 8, e69430. [Google Scholar] [CrossRef]
- Shimakawa, Y.; Lemoine, M.; Njai, H.F.; Bottomley, C.; Ndow, G.; Goldin, R.D.; Jatta, A.; Jeng-Barry, A.; Wegmuller, R.; E Moore, S.; et al. Natural history of chronic HBV infection in West Africa: A longitudinal population-based study from The Gambia. Gut 2016, 65, 2007–2016. [Google Scholar] [CrossRef]
- Szmuness, W.; Stevens, C.E.; Zang, E.A.; Harley, E.J.; Kellner, A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report. Hepatology 1981, 1, 377–385. [Google Scholar] [CrossRef]
- Breakwell, L.; Tevi-Benissan, C.; Childs, L.; Mihigo, R.; Tohme, R. The status of hepatitis B control in the African region. Pan Afr. Med. J. 2017, 27 (Suppl. S3), 17. [Google Scholar] [CrossRef] [PubMed]
- Hepatitis B Vaccination Coverage [Internet]. 2021. Available online: https://immunizationdata.who.int/pages/coverage/hepb.html?GROUP=WHO%20Regions&ANTIGEN=&YEAR=&CODE= (accessed on 28 November 2021).
- Wilson, P.; Parr, J.B.; Jhaveri, R.; Meshnick, S.R. Call to Action: Prevention of Mother-to-Child Transmission of Hepatitis B in Africa. J. Infect. Dis. 2018, 217, 1180–1183. [Google Scholar] [CrossRef] [Green Version]
- Moturi, E.; Tevi-Benissan, C.; Hagan, J.E.; Shendale, S.; Mayenga, D.; Murokora, D.; Patel, M.; Hennessey, K.; Mihigo, R. Implementing a Birth Dose of Hepatitis B Vaccine in Africa: Findings from Assessments in 5 Countries. J. Immunol. Sci. 2018, (Suppl. S5), 31–40. [Google Scholar] [CrossRef] [Green Version]
- Pley, C.M.; McNaughton, A.L.; Matthews, P.C.; Lourenço, J. The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. BMJ Glob. Health 2021, 6, e004275. [Google Scholar] [CrossRef] [PubMed]
- Otto, B.F.; Suarnawa, I.M.; Stewart, T.; Nelson, C.; Ruff, T.A.; Widjaya, A.; Maynard, J.E. At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine 1999, 18, 498–502. [Google Scholar] [CrossRef]
- Seaman, C.P.; Morgan, C.; Howell, J.; Xiao, Y.; Spearman, C.W.; Sonderup, M.; Lesi, O.; Andersson, M.I.; Hellard, M.E.; Scott, N. Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: A modelling and cost-optimisation study. Lancet Glob. Health 2020, 8, e931–e941. [Google Scholar] [CrossRef]
- Bigna, J.J.; Kenne, A.M.; Hamroun, A.; Ndangang, M.S.; Foka, A.J.; Tounouga, D.N.; Lenain, R.; Amougou, M.A.; Nansseu, J.R. Gender development and hepatitis B and C infections among pregnant women in Africa: A systematic review and meta-analysis. Infec. Dis. Poverty 2019, 8, 16. [Google Scholar] [CrossRef] [Green Version]
- Spearman, C.W.; Afihene, M.; Ally, R.; Apica, B.; Awuku, Y.; Cunha, L.; Dusheiko, G.; Gogela, N.; Kassianides, C.; Kew, M.; et al. Hepatitis B in sub-Saharan Africa: Strategies to achieve the 2030 elimination targets. Lancet Gastroenterol. Hepatol. 2017, 2, 900–909. [Google Scholar] [CrossRef] [Green Version]
- WHO. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy; WHO: Geneva, Switzerland, 2020. [Google Scholar]
- Funk, A.L.; Lu, Y.; Yoshida, K.; Zhao, T.; Boucheron, P.; van Holten, J.; Chou, R.; Bulterys, M.; Shimakawa, Y. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: A systematic review and meta-analysis. Lancet Infect. Dis. 2021, 21, 70–84. [Google Scholar] [CrossRef]
- Cohn, J.; Owiredu, M.N.; Taylor, M.M.; Easterbrook, P.; Lesi, O.; Francoise, B.; Broyles, L.N.; Mushavi, A.; Van Holten, J.; Ngugi, C.; et al. Eliminating mother-to-child transmission of human immunodeficiency virus, syphilis and hepatitis B in sub-Saharan Africa. Bull. World Health Organ. 2021, 99, 287–295. [Google Scholar] [CrossRef] [PubMed]
- Wang, A.-L.; Qiao, Y.-P.; Wang, L.-H.; Fang, L.-W.; Wang, F.; Jin, X.; Qiu, J.; Wang, X.-Y.; Wang, Q.; Wu, J.-L.; et al. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China. Bull. World Health Organ. 2014, 93, 52–56. [Google Scholar] [CrossRef] [PubMed]
- Zhang, L.; Tao, Y.; Woodring, J.; Rattana, K.; Sovannarith, S.; Rathavy, T.; Cheang, K.; Hossain, S.; Ferradini, L.; Deng, S.; et al. Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: An economic evaluation. Int. J. Epidemiol. 2019, 48, 1327–1339. [Google Scholar] [CrossRef]
- Sonderup, M.W.; Dusheiko, G.; Desalegn, H.; Lemoine, M.; Tzeuton, C.; Taylor-Robinson, S.D.; Spearman, C.W. Hepatitis B in sub-Saharan Africa-How many patients need therapy? J. Viral Hepat. 2020, 27, 560–567. [Google Scholar] [CrossRef]
- WHO. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection; WHO: Geneva, Switzerland, 2015. [Google Scholar]
- Aberra, H.; Desalegn, H.; Berhe, N.; Mekasha, B.; Medhin, G.; Gundersen, S.G.; Johannessen, A. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. J. Hepatol. 2019, 70, 1065–1071. [Google Scholar] [CrossRef] [PubMed]
- Dusheiko, G.; Lemoine, M. An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans. J. Hepatol. 2019, 70, 1046–1048. [Google Scholar] [CrossRef] [Green Version]
- Desalegn, H.; Aberra, H.; Berhe, N.; Gundersen, S.G.; Johannessen, A. Are non-invasive fibrosis markers for chronic hepatitis B reliable in sub-Saharan Africa? Liver Int. 2017, 37, 1461–1467. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Umutesi, G.; Shumbusho, F.; Kateera, F.; Serumondo, J.; Kabahizi, J.; Musabeyezu, E.; Ngwije, A.; Gupta, N.; Nsanzimana, S. Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa. J. Hepatol. 2019, 70, 1043–1045. [Google Scholar] [CrossRef] [Green Version]
- Shimakawa, Y.; Ndow, G.; Njie, R.; Njai, H.F.; Takahashi, K.; Akbar, S.M.F.; Cohen, D.; Nayagam, S.; Jeng, A.; Ceesay, A.; et al. Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. Clin. Infect. Dis. 2020, 70, 1442–1452. [Google Scholar] [CrossRef]
- Shimakawa, Y.; Vernoux, L.; Gabassi, A.; Mercier-Delarue, S.; Vincent, J.P.; Simon, F.; Maylin, S. Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS). J. Viral Hepat. 2021, 28, 837–843. [Google Scholar] [CrossRef]
- Brunetto, M.R.; Carey, I.; Maasoumy, B.; Marcos-Fosch, C.; Boonstra, A.; Caviglia, G.P.; Loglio, A.; Cavallone, D.; Scholtes, C.; Ricco, G.; et al. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. Aliment. Pharmacol. Ther. 2021, 53, 733–744. [Google Scholar]
- Yoshida, K.; Desbiolles, A.; Feldman, S.F.; Ahn, S.H.; Alidjinou, E.K.; Atsukawa, M.; Bocket, L.; Brunetto, M.R.; Buti, M.; Carey, I.; et al. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clin. Gastroenterol. Hepatol. 2021, 19, 46–60.e8. [Google Scholar] [CrossRef]
- Njai, H.F.; Shimakawa, Y.; Sanneh, B.; Ferguson, L.; Ndow, G.; Mendy, M.; Sow, A.; Lo, G.; Toure-Kane, C.; Tanaka, J.; et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. J. Clin. Microbiol. 2015, 53, 1156–1163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lemoine, M.; Shimakawa, Y.; Njie, R.; Taal, M.; Ndow, G.; Chemin, I.; Ghosh, S.; Njai, H.F.; Jeng, A.; Sow, A.; et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: The Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob. Health 2016, 4, e559–e567. [Google Scholar] [CrossRef] [Green Version]
- Buti, M.; Gane, E.; Seto, W.K.; Chan, H.L.; Chuang, W.L.; Stepanova, T.; Hui, A.-J.; Lim, Y.-S.; Mehta, R.; Janssen, H.L.A.; et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol. Hepatol. 2016, 1, 196–206. [Google Scholar] [CrossRef]
- Afican Union Cairo Declaration on Viral Hepatitis in Africa. 2020. Available online: https://au.int/sites/default/files/newsevents/workingdocuments/36768-wd-sa24616_e_original_declaration_on_viral_hepatitis.pdf (accessed on 2 July 2019).
Country | HBsAg Sero-Prevalence |
---|---|
Algeria | 1.8 |
Angola | 9.4 |
Benin | 11 |
Botswana | 1.3 |
Burkina Faso | 10.1 |
Burundi | 6.4 |
Cabo Verde | 5.2 |
Cameroon | 4.4 |
Central African Republic | 10.2 |
Chad | 4.9 |
Comoros | 4.3 |
Congo | 9.5 |
Cote-d’Ivore | 6.1 |
Eswatini | 3.2 |
Equatorial Guinea | 9.3 |
Eritrea | 1.9 |
Ethiopia | 5.7 |
Gabon | 9.1 |
The Gambia | 5.8 |
Ghana | 8.6 |
Guinea | 13 |
Guinea Bissau | 5.1 |
Kenya | 2.2 |
Lesotho | 4.5 |
Liberia | 14.9 |
Madagascar | 8.2 |
Malawi | 6.9 |
Mali | 8.5 |
Mauritania | 10.2 |
Mauritius | 1.9 |
Mozambique | 7.2 |
Namibia | 2.2 |
Niger | 11.6 |
Nigeria | 5.5 |
Rwanda | 4.5 |
São Tomé and Principe | 5.5 |
Senegal | 8.2 |
Seychelles | 0.4 |
Sierra Leone | 8.6 |
South Africa | 6.1 |
South Sudan | 22.2 |
Tanzania | 4 |
Togo | 8.4 |
Uganda | 6.3 |
Zambia | 4.1 |
Zimbabwe | 10.1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sonderup, M.W.; Spearman, C.W. Global Disparities in Hepatitis B Elimination—A Focus on Africa. Viruses 2022, 14, 82. https://doi.org/10.3390/v14010082
Sonderup MW, Spearman CW. Global Disparities in Hepatitis B Elimination—A Focus on Africa. Viruses. 2022; 14(1):82. https://doi.org/10.3390/v14010082
Chicago/Turabian StyleSonderup, Mark W., and C. Wendy Spearman. 2022. "Global Disparities in Hepatitis B Elimination—A Focus on Africa" Viruses 14, no. 1: 82. https://doi.org/10.3390/v14010082
APA StyleSonderup, M. W., & Spearman, C. W. (2022). Global Disparities in Hepatitis B Elimination—A Focus on Africa. Viruses, 14(1), 82. https://doi.org/10.3390/v14010082